{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:42:43Z","timestamp":1794411763371,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cyto.2024.156620","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:21:05Z","timestamp":1714684865000},"page":"156620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Baricitinib protects ICIs-related myocarditis by targeting JAK1\/STAT3 to regulate Macrophage polarization"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3693-7404","authenticated-orcid":false,"given":"Xuejun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cyto.2024.156620_b0005","doi-asserted-by":"crossref","first-page":"e002553","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.cyto.2024.156620_b0010","doi-asserted-by":"crossref","unstructured":"Johnson D B, Balko J M, Compton M L, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander M R, Bloomer T L, Becker J R, Slosky D A, Phillips E J, Pilkinton M A, Craig-Owens L, Kola N, Plautz G, Reshef D S, Deutsch J S, Deering R P, Olenchock B A, Lichtman A H, Roden D M, Seidman C E, Koralnik I J, Seidman J G, Hoffman R D, Taube J M, Diaz L A, Jr., Anders R A, Sosman J A, Moslehi J J. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med, 2016; 375(18): 1749-1755.","DOI":"10.1056\/NEJMoa1609214"},{"key":"10.1016\/j.cyto.2024.156620_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.721333","article-title":"Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: uncovering etiological mechanisms","volume":"8","author":"Rikhi","year":"2021","journal-title":"Front Cardiovasc Med."},{"issue":"1","key":"10.1016\/j.cyto.2024.156620_b0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCRESAHA.118.312017","article-title":"Metabolic coordination of physiological and pathological cardiac remodeling","volume":"123","author":"Gibb","year":"2018","journal-title":"Circ Res."},{"key":"10.1016\/j.cyto.2024.156620_b0025","first-page":"ehab842","article-title":"Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies","author":"Steffens","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.cyto.2024.156620_b0030","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/CIRCULATIONAHA.120.050682","article-title":"MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload","volume":"143","author":"Ramanujam","year":"2021","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.cyto.2024.156620_b0035","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1161\/CIRCRESAHA.119.316428","article-title":"Self-maintenance of cardiac resident reparative macrophages attenuates doxorubicin-induced cardiomyopathy through the SR-A1-c-Myc Axis","volume":"127","author":"Zhang","year":"2020","journal-title":"Circ Res."},{"key":"10.1016\/j.cyto.2024.156620_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117559","article-title":"Macrophages: first guards in the prevention of cardiovascular diseases","volume":"250","author":"Nasser","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2024.156620_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799077","article-title":"Case report: glucocorticoid effect observation in a ureteral urothelial cancer patient with ici-associated myocarditis and multiple organ injuries","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156620_b0050","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/en.2014-1048","article-title":"From receptor balance to rational glucocorticoid therapy","volume":"155","author":"de Kloet","year":"2014","journal-title":"Endocrinology."},{"issue":"5","key":"10.1016\/j.cyto.2024.156620_b0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"issue":"3","key":"10.1016\/j.cyto.2024.156620_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102750","article-title":"Working and safety profiles of JAK\/STAT signaling inhibitors. are these small molecules also smart?","volume":"20","author":"Favoino","year":"2021","journal-title":"Autoimmun Rev."},{"issue":"4","key":"10.1016\/j.cyto.2024.156620_b0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156620_b0070","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"12","key":"10.1016\/j.cyto.2024.156620_b0075","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.40680","article-title":"Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis","volume":"70","author":"Tanaka","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.cyto.2024.156620_b0080","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/s41375-021-01266-6","article-title":"JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis","volume":"35","author":"Chen","year":"2021","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.cyto.2024.156620_b0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2024.156620_b0090","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/bjd.17344","article-title":"A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus","volume":"180","author":"Werth","year":"2019","journal-title":"Br J Dermatol."},{"issue":"7","key":"10.1016\/j.cyto.2024.156620_b0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.cyto.2024.156620_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109955","article-title":"Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors","volume":"37","author":"He","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cyto.2024.156620_b0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2021.01.009","article-title":"The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy","volume":"331","author":"Kwon","year":"2021","journal-title":"J Control Release."},{"issue":"4","key":"10.1016\/j.cyto.2024.156620_b0110","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.7150\/thno.45777","article-title":"Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy","volume":"11","author":"Cai","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.cyto.2024.156620_b0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.cyto.2024.156620_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.immuni.2013.11.019","article-title":"Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation","volume":"40","author":"Epelman","year":"2014","journal-title":"Immunity."},{"issue":"12","key":"10.1016\/j.cyto.2024.156620_b0125","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCRESAHA.121.319737","article-title":"Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis","volume":"129","author":"Revelo","year":"2021","journal-title":"Circ Res."},{"key":"10.1016\/j.cyto.2024.156620_b0130","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jacc.2018.08.2149","article-title":"The macrophage in cardiac homeostasis and disease: JACC macrophage in CVD series (Part 4)","volume":"72","author":"Lavine","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cyto.2024.156620_b0135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","article-title":"Cardioimmunology: the immune system in cardiac homeostasis and disease","volume":"18","author":"Swirski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2024.156620_b0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/cvr\/cvu025","article-title":"Cardiac macrophages and their role in ischaemic heart disease","volume":"102","author":"Frantz","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.cyto.2024.156620_b0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2019.06.007","article-title":"The cardiac microenvironment instructs divergent monocyte fates and functions in myocarditis","volume":"28","author":"Hou","year":"2019","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.cyto.2024.156620_b0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11886-020-01278-1","article-title":"Autoimmunity in acute myocarditis: how immunopathogenesis steers new directions for diagnosis and treatment","volume":"22","author":"Bruestle","year":"2020","journal-title":"Curr Cardiol Rep."},{"issue":"7","key":"10.1016\/j.cyto.2024.156620_b0155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","article-title":"Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling","volume":"11","author":"Xia","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2024.156620_b0160","doi-asserted-by":"crossref","first-page":"e140685","DOI":"10.1172\/JCI140685","article-title":"Macrophage-produced VEGFC is induced by efferocytosis to ameliorate cardiac injury and inflammation","author":"Glinton","year":"2022","journal-title":"J Clin Invest."},{"issue":"7","key":"10.1016\/j.cyto.2024.156620_b0165","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","article-title":"Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment","volume":"79","author":"Xiong","year":"2019","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cyto.2024.156620_b0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41569-019-0164-7","article-title":"T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword","volume":"16","author":"Simons","year":"2019","journal-title":"Nat Rev Cardiol."},{"issue":"9","key":"10.1016\/j.cyto.2024.156620_b0175","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/jcp.29593","article-title":"Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases","volume":"235","author":"Hosseini","year":"2020","journal-title":"J Cell Physiol."},{"issue":"24","key":"10.1016\/j.cyto.2024.156620_b0180","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood.2020009023","article-title":"A JAK\/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML","volume":"137","author":"Chen","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.cyto.2024.156620_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharmacol Res."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T22:00:28Z","timestamp":1718748028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624001236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":37,"alternative-id":["S1043466624001236"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156620","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib protects ICIs-related myocarditis by targeting JAK1\/STAT3 to regulate Macrophage polarization","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156620"}}